Methodist Journal

IN THIS ISSUE

Diabetes and the Heart

Vol 14, Issue 4 (2019)


FEATURED GUEST EDITOR

ISSUE INTRO

The Intersection of Diabetes and Cardiovascular Disease

See More
RECOGNITIONS

Guest Editors Steven Petak and Archana Sadhu Guide Issue on Diabetes and the Heart

See More

REVIEW ARTICLES See More

Cardiac Autonomic Neuropathy in Diabetes Mellitus

Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure

Imaging to Stratify Coronary Artery Disease Risk in Asymptomatic Patients with Diabetes

Update on Management of Type 2 Diabetes for Cardiologists

New Therapeutic Strategies for Type 2 Diabetes

Prediabetes: Why Should We Care?

Central Venous Pathologies: Treatments and Economic Impact

Venous Thrombosis and Post-Thrombotic Syndrome: From Novel Biomarkers to Biology

CASE REPORTS See More

Loperamide Mimicking Brugada Pattern

Reversed Pulsus Paradoxus in Right Ventricular Failure

Mycobacterium Chimaera Mimicking Sarcoidosis

Immune Checkpoint Inhibitor Related Cardiotoxicity

MUSEUM OF HMH MULTIMODALITY IMAGING CENTER See More

A Right Ventricular Mass

CLINICAL PERSPECTIVES See More

POINTS TO REMEMBER

The Kidney as an Endocrine Organ

EXCERPTA

The Other Side of the Prescription

EXCERPTA

Telemedicine Shakes Up the ICU Experience

POINTS TO REMEMBER

Venous Thrombosis in Nephrotic Syndrome

EDITORIALS

Letter to the Editor in response to “Role of Subcutaneous Leadless Implantable Cardioverter Defibrillator in Young Patients

Vol 14, Issue 4 (2019)

Article Dialogue

Prediabetes: Why Should We Care?

Jump to:
Article Citation:

Ashkan Zand, M.D., et al. Nucleic Acid Delivery for Endothelial Dysfunction in Cardiovascular Diseases. Methodist DeBakey Cardiovascular Journal. 2018;14(4):246-310.



Abstract

A clear link between cardiovascular disease and prediabetes has emerged over the past few years. Recent studies have shown that patients with prediabetes can suffer from coronary artery disease and diastolic heart failure even before progressing to overt diabetes. With this knowledge, physicians must identify prediabetes and take appropriate measures to optimize glycemic control. The pathophysiological defect seen in prediabetes can be managed with lifestyle modifications; thus, it is essential that physicians have a clear understanding of the current recommendations regarding diet and exercise. This review outlines the complications associated with prediabetes, presents an overview of the available pharmacological and surgical therapies that are effective in treating it, and provides a stepwise, multipronged approach for management.

Keywords

prediabetes, impaired fasting glucose, impaired glucose tolerance, diabetes prevention, management of prediabetes

INTRODUCTION

The 2017 National Diabetes Statistics Report from the U.S. Centers for Disease Control and Prevention estimates that 33.9% of the adult U.S. population has prediabetes based on either fasting glucose or hemoglobin A1c (HbA1c) levels. The prevalence is higher in those aged 65 years and older, at 48.3%. Not surprisingly, only 11.6% of U.S. adults know they have prediabetes.1

Diagnosis of prediabetes is based on the presence of impaired fasting glucose, impaired glucose tolerance, and/or elevated HbA1c levels between 5.7% and 6.4%.2 Impaired glucose tolerance is defined as blood glucose levels of 140 to 199 mg/dL during a 75-gram oral glucose tolerance test (normal < 140 mg/dL), and impaired fasting glucose is defined as blood glucose levels of 100 to 125 mg/dL, although the World Health Organization has a narrower threshold of  between 110 and 125 mg/dL).3 In multiple studies, prediabetes is shown to have a cause-effect relationship to cardiovascular disease and all-cause mortality. In a cohort meta-analysis by Huang et al., prediabetes was associated with an increased risk of coronary heart disease, stroke, and all-cause mortality.4

Focusing on lifestyle and medical management of prediabetes, this review highlights the systemic and, in particular, cardiac complications associated with prediabetes, with the goal of providing tools for healthcare providers to treat this patient population and provide secondary preventative measures.

CARDIAC COMPLICATIONS OF PREDIABETES

The prediabetes state is not only a noteworthy risk factor for type 2 diabetes but is also a significant risk factor for macrovascular disease. Although some of the risk may be due to the progression to overt diabetes, an independent risk is still present in individuals who have not yet progressed to diabetes.5 A meta-analysis of 38 prospective studies in which cardiovascular disease (CVD) or mortality was the end point concluded that increasing glucose levels displayed a linear relationship with CVD risk.6

The macrovascular complications from prediabetes typically arise due to atherosclerosis. Because prediabetes and metabolic syndrome often coexist, the risk of developing an atheroma is high. In addition, strong evidence suggests that patients with prediabetes have an increase in fibrinogen and high-sensitivity C-reactive protein (hs-CRP)—both proatherogenic factors—compared with normoglycemic patients.7,8 This section focuses mainly on the macrovascular complications associated with prediabetes, specifically coronary artery disease and heart failure.

Coronary Artery Disease

While most recognize a direct link between diabetes and coronary artery disease, few physicians and patients acknowledge the potential risk associated with a prediabetes diagnosis. Sen et al. conducted a study on 62 acute coronary syndrome patients who were admitted to a tertiary facility in India to identify the proportion that had prediabetes; they discovered that 48.4% of this patient population had prediabetes and 25% had diabetes.9

In a study by the American Diabetes Association (ADA)10 on the impact of prediabetes on coronary artery atherosclerosis, 67 patients with established coronary artery disease (CAD) underwent angioscopic evaluation of multiple main trunk arteries. Per ADA guidelines, 16 of the patients were classified as nondiabetic, 28 were considered prediabetic, and 23 were diabetic. Yellow plaques identified by angioscopy are commonly considered the primary lesion in acute coronary syndromes, and the presence of two or more per vessel is considered to be a risk factor for future cardiac events. All groups were assessed for both the number of yellow plaques per vessel and intensity of yellow grade. The number and grade of yellow plaques were higher in the prediabetic patients than in nondiabetics (P = .02 and P = .04, respectively) but similar in both prediabetic and diabetic patients (P = .44 and P = .21, respectively). In multivariate logistic regression analysis, both diabetes and prediabetes were independent predictors of multiple yellow plaques.10 In a larger study done by Scicali et al., the impact of prediabetes on coronary artery calcium (CAC) scores and mean common carotid media thickness (IMT) was compared in prediabetic patients and nondiabetic patients. Of the 272 patients enrolled, both the CAC scores and mean IMT were significantly higher in the prediabetes group (P < .001 and P < .001, respectively).11 In conclusion, a prediabetes state could potentially have a similar impact as diabetes on coronary and peripheral atherosclerosis. Larger studies are needed in the prediabetes population to establish a direct link between prediabetes and CAD.

Diastolic Heart Failure

Although studies such as the Framingham Heart Study have established an epidemiologic link between diabetes and heart failure,12 there is no established pathophysiologic association between prediabetes and cardiac function in humans. In an experimental animal model, Koncsos et al. aimed to better define the relationship between prediabetes and diastolic heart failure by administering a single low dose of streptozotocin to Long Evans rats fed with high-fat chow. This treatment induced prediabetes as characterized by a slight elevation in fasting blood glucose, impaired glucose and insulin tolerance, and an increase in visceral adipose tissue. The cardiac consequence of a metabolic derangement such as prediabetes was assessed in this setting. Measurement of morphological and functional parameters of the hearts, as assessed by echocardiography, determined that left ventricular (LV) mass as well as LV anterior and posterior wall thickness were increased in prediabetes rats. Other cardiac dimensional parameters remained unchanged. The slope of the LV end-diastolic pressurevolume relationship, an early and sensitive indicator of diastolic dysfunction, was elevated in the prediabetes group. Pathological evaluation revealed increased oxidative mitochondrial stress and increased mitofusin-2 (MFN2) levels in vascular smooth muscle. Increased MFN2 is thought to induce apoptotic cell death in rat cardiomyocytes.13 Of note, in a previous study by Essop et al., cardiac mitochondrial oxidative stress in male Wistar rats was not seen even after 16 weeks, indicating that mitochondrial oxidative stress might not be present in all models and stages of prediabetes.14 Di Pino et al. studied the effects of prediabetes on diastolic function in 167 patients with HbA1c between 5.7% and 6.4%. In patients with prediabetes, they found a significantly lower peak mitral inflow in early diastole (E wave) to late diastolic atrial filling velocity (A wave) ratio (P < .05), a higher left atrium volume (LAV) (P < .05), and a higher sphericity index (SI) (P < .05) when compared to controls. The E/A ratio, LAV, and SI are all early signs of diastolic dysfunction.15

LIFESTYLE MODIFICATIONS

The combination of diet and exercise is arguably the single most important factor that could halt the progression towards type 2 diabetes in patients with prediabetes. Among the first studies to prove this was the Finnish Diabetes Prevention Study (DPS), a controlled randomized trial including 522 overweight subjects with impaired glucose tolerance who were randomized to either an intensive lifestyle intervention group or a standard-of-care control group.16 The intensive lifestyle intervention group received individualized dietary counseling and circuit-type resistance training and were advised to increase overall physical activity, whereas the control group received general counseling on diet and exercise along with an annual physical exam. The lifestyle intervention arm of the study was designed to be at a high intensity during the first year, followed by a maintenance period, with the goal of reducing both weight and dietary fat intake while increasing physical activity and dietary fiber. Weight reductions were measured after 1 year and at 3 years; the intervention group lost 4.5 kg and 3.5 kg while the control group lost 1.0 and 0.9 kg, respectively. Lipid and glycemic parameters showed more improvement in the intervention group, with a 58% reduction in the risk of developing diabetes compared to the control group. The subjects who were free of diabetes at the end of the intervention were followed up for an additional 3 years, and the incidence of diabetes, physical activity, and dietary intake of fiber and fat was measured. During the total 7-year follow-up period,17 the study concluded that the incidence of type 2 diabetes was 4.3 versus 7.4 per 100 person-years in the intervention and control group, respectively (log-rank test P = .0001), indicating a 36% reduction in relative risk.

Figure 1. Lifestyle interventions in prediabetes; adapted from American Association of Clinical Endocrinologists guidelines.22

Another large study that reproduced similar results was from the Diabetes Prevention Program (DPP), which was similar to the Finnish study in its design but included a group treated with metformin for comparison.18 A total of 3,234 high-risk adults were recruited; 1,079 participants underwent intensive lifestyle intervention, 924 were treated with metformin, and 932 were treated with a placebo. The lifestyle group achieved two important goals: loss of 7% of their initial body weight and a minimum of 150 min of physical activity per week (at an intensity similar to brisk walking). Diabetes incidence was reduced by 58% in the lifestyle group and by 31% with metformin compared to placebo. Analysis was by intention-to-treat, with one case of diabetes prevented for every 6.9 people. Further analysis of the lifestyle group showed a 16% reduction in diabetes risk for every kilogram of weight loss.19 After a 10-year follow-up, the study concluded that the effects of lifestyle modification on diabetes prevention were maintained.

Both the Finnish and DPP studies were successful in demonstrating that lifestyle intervention is a valuable key to managing prediabetes. However, the challenge still remains in implementing these methods in a community setting. Katula et al. applied the methods of the DPP study to the local community via key modifications to enhance efficiency and feasibility.20 Community healthcare workers with well-controlled diabetes and a history of a healthy lifestyle were recruited to deliver a group-based lifestyle weight loss (LWL) intervention through a partnership with a community-based diabetes educational program. The study recruited 301 obese volunteers who were prediabetic on at least two occasions. The LWL intervention had two valuable goals for their participants: a calorie intake between 1,200 and 1,800 kcal per day, and &#8805; 180 min of physical activity per week. This approach is in agreement with parameters set by the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society of Clinical Nutrition.21 Participants were present at 67.7% of all group intervention sessions. On an adjusted average of the 6- and 12-month means, LWL intervention participants had a net weight loss of 6.0% of their body weight and 5.0 cm in waist circumference compared to standard of care patients. There was also a 4.3 mg/dL decrease in fasting glucose in the LWL intervention participants versus a decrease of 0.4 mg/dL in the standard of care patients (P < .001).

PHARMACOLOGICAL AGENTS

There are currently four medications for treating the prediabetes subpopulation, including metformin, pioglitazone, acarbose, and liraglutide. In addition, the American Association of Clinical Endocrinologists (AACE) has also proposed three weight-loss therapies—including orlistat, lorcaserin, and phentermine/topiramate ER—to manage obesity with the goal of halting the progression of insulin resistance and type 2 diabetes (Figure 1).22 No data is available for naltrexone/bupropion. Table 1 provides an extensive review of the currently available pharmacological agents.23-40

Table 1a. Summary of current medications to treat prediabetes.23-40 T2DM: type 2 diabetes mellitus; MI: myocardial infarction; CVD: cardiovascular disease
Table 1b. Summary of current medications to treat prediabetes.23-40 T2DM: type 2 diabetes mellitus; MI: myocardial infarction; CVD: cardiovascular disease
Table 1c. Summary of current medications to treat prediabetes.23-40 T2DM: type 2 diabetes mellitus; MI: myocardial infarction; CVD: cardiovascular disease
Table 1d. Summary of current medications to treat prediabetes.23-40 T2DM: type 2 diabetes mellitus; MI: myocardial infarction; CVD: cardiovascular disease

BARIATRIC SURGERY

In 2011, the American College of Surgeons Bariatric Surgery Center Network (ACS-BSCN) recognized bariatric surgery as a potential intervention for type 2 diabetes and prediabetes in addition to assisting in weight loss in morbidly obese patients. De la Cruz-Muñozand colleagues performed a retrospective analysis of 1,602 adults who underwent bariatric surgery; they were categorized into those with diagnosed type 2 diabetes, those with prediabetes, those with high fasting plasma glucose (FPG), and those with normal FPG. At 1- and 3-year follow-up post bariatric surgery, all four groups had normal FPG, but the prediabetes group had more significant weight loss (47 kg) than the diabetes population.41 Procedures such as the Roux-en-Y gastric bypass and the biliopancreatic diversion have been shown to be the most effective for patients with diabetes.42 Normalization of plasma glucose concentrations, HbA1c, and insulin levels were seen in 80% to 100% of patients within days post-surgery prior to any weight loss. The above findings could be attributed to reduced food intake, malabsorption of nutrients, and alterations in gastrointestinal anatomy that incite changes in the incretin system.

Among obese patients (body mass index > 40) who are candidates for bariatric surgery, prediabetes patients should be prioritized because they are at higher risk of diabetes and complications that can be prevented with surgery and the subsequent weight loss. This is supported by a post hoc analysis of 4,032 participants from the Swedish Obese Subjects study, half of whom had bariatric surgery and the other half receiving usual care. After 15 years of follow-up, patients in the diabetes, prediabetes, and normoglycemic groups who underwent bariatric surgery had a reduced incidence of macrovascular complications. Interestingly, the largest risk reduction for macrovascular complications was seen in the prediabetes group.43

CONCLUSION

The link between prediabetes and cardiovascular disease has been clearly established, and physicians should be aware of the implications for their patients. At this time, major organizations such as the AACE have publish written statements on the importance of diagnosing and treating the prediabetes population. Following these steps will help ensure that future complications in this subpopulation will not take a toll on our healthcare system.

The first step in managing patients with prediabetes is to encourage strict lifestyle modifications consisting of &#8805; 180 min of physical activity per week and a calorie intake of 1,200 to 1,800 kcal per day. Providers can also refer their patients to ancillary providers, such as dieticians or weight management specialists, who can help them achieve their goals. In addition to lifestyle management, anti-obesity agents such as orlistat, lorcaserin, and phentermine/topiramate should be considered for obese patients with prediabetes.

Healthcare providers can also consider pharmacologic agents (metformin, pioglitazone, liraglutide, or acarbose) for management of prediabetes. Each of these drugs has a safe pharmacologic profile with regard to hypoglycemia. Metformin has a good track record of being a safe, tolerable drug with benefits such as modest weight loss and a potential cardioprotective effect. Pioglitazone (e.g., Actos) is another viable option due to its ability to increase insulin sensitivity and its known advantage in secondary prevention among stroke/myocardial infarction patients; however, it is also known to cause side effects such as weight gain and bone fractures in the osteoporotic population. If weight loss is a desired effect, providers can consider liraglutide, a weight-loss agent approved by the U.S. Food and Drug Administration that has been shown to improve glycemic control and HbA1c levels.

If medical management fails to achieve glycemic control, advanced measures such as bariatric surgery can be used with the goal of reversing prediabetes and helping obese patients lose weight. All surgical procedures are complex processes that require mental preparedness on the part of the patient and an in-depth understanding of how it will impact their lifestyle; thus, surgery should be reserved for those who are resistant to other forms of treatment. Providers should not be discouraged from sending patients who meet surgical criteria to bariatric surgical centers since studies have shown that surgery can control prediabetes and improve both lipid profiles and blood pressure.

In short, providers can help patients with prediabetes through multiple means and should use the above tools in their arsenal. Providers should also feel comfortable referring patients to an endocrinologist when the clinical picture is complex enough to require multidisciplinary care.

KEY POINTS

  • Prediabetes is a growing concern as it affects roughly 33.9% of U.S. adults, with the majority of this population left untreated.
  • Complications of prediabetes include macrovascular effects such as myocardial infraction, stroke, and peripheral vascular disease as well as microvascular changes such as retinopathy, neuropathy, and nephropathy.
  • Healthcare providers should start screening for prediabetes and initiate treatment as soon as possible, starting with lifestyle interventions and progressing to pharmacologic therapies.
  • Health providers should consider a multidisciplinary approach by involving a certified diabetes educator and/or nutritionist and recruiting additional support from an endocrinologist or bariatric surgeon as needed.
Conflict of Interest Disclosure

The authors have completed and submitted the Methodist DeBakey Cardiovascular Journal Conflict of Interest Statement and none were reported.

RELATED ARTICLES

Cardiac Autonomic Neuropathy in Diabetes Mellitus

Shruti Agashe, M.D.

Agashe S, Petak S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist DeBakey Cardiovasc J. 2018;14(4):251-256.

Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure

Patricia Mejia Osuna, M.D.

Osuna PM, Brown SJ, Tabatabai LS, Hamilton DJ. Stage-Based Management of Type 2 Diabetes Mellitus with Heart Failure. Methodist DeBakey Cardiovasc J. 2018;14(4):257-65.

Imaging to Stratify Coronary Artery Disease Risk in Asymptomatic Patients with Diabetes

Maan Malahfji, M.D.

Malahfji M, Mahmarian JJ. Imaging to Stratify Coronary Artery Disease Risk in Asymptomatic Patients with Diabetes. Methodist DeBakey Cardiovasc J. 2018;266-72.

Add Comments

Please login to dialogue with author.

Comments